key: cord-0695049-krkcpjlm
authors: Perera, Krishani Dinali; Johnson, David; Lovell, Scott; Groutas, William; Chang, Kyeong-Ok; Kim, Yunjeong
title: Potent protease inhibitors of deadly lagoviruses: rabbit hemorrhagic disease virus and European brown hare syndrome virus
date: 2022-01-10
journal: bioRxiv
DOI: 10.1101/2022.01.10.474982
sha: ee7bdfa356bf10759a3d005091c77de38f62a186
doc_id: 695049
cord_uid: krkcpjlm

Rabbit hemorrhagic disease (RHD) and European brown hare syndrome (EBHS) are highly contagious diseases caused by lagoviruses in the Caliciviridae family and mainly affect rabbits and hares, respectively. These infectious diseases are associated with high mortality and a serious threat to domesticated and wild rabbits and hares, including endangered species such as Riparian brush rabbits. In the US, only isolated cases of RHD had been reported until Spring 2020. However, RHD caused by RHD type 2 virus (RHDV2) was unexpectedly reported in April 2020 in New Mexico and has subsequently spread to several US states infecting wild rabbits and hares, making it highly likely that RHD will become endemic in the US. Vaccines are available for RHD, however, there is no specific treatment for these diseases. RHDV and EBHSV encode a 3C-like protease (3CLpro), which is essential for virus replication and a promising target for antiviral drug development. We have previously generated focused small molecule libraries of 3CLpro inhibitors and demonstrated the in vitro potency and in vivo efficacy of some protease inhibitors against viruses that encode 3CLpro including caliciviruses and coronaviruses. Here we established the enzyme and cell-based assays for these uncultivable viruses to determine the in vitro activity of 3CLpro inhibitors, including GC376, a protease inhibitor being developed for feline infectious peritonitis, and identified potent inhibitors of RHDV1 and 2 and EBHSV. In addition, structure-activity relationship study and homology modelling of the 3CLpros and inhibitors revealed that lagoviruses share similar structural requirements for 3CLpro inhibition with other caliciviruses.

Rabbit hemorrhagic disease (RHD) is a highly contagious viral disease of domesticated (farmed and pet) and wild rabbits with high mortality, which can reach up to 70~100% (Gleeson and Petritz, 2020) . RHD is caused by rabbit hemorrhagic disease virus (RHDV) type 1 or 2, which belong to the genus Lagovirus in the Caliciviridae family ( Fig. 1A ) (Adams et al., 2017) . The classical type 1 RHDV (RHDV1) was first reported in 1984 in China among rabbits imported from Germany, and its variant type 2 RHDV (RHDV2) emerged in 2010 in France (Le Gall-Recule et al., 2011) . Since then, RHDV type 1 and 2 infections have become endemic in most parts of the world, including Australia, New Zealand, parts of Asia and most of Europe (Cancellotti and Renzi, 1991) , and in some regions RHDV2 mostly replaced RHDV1. In the US, only sporadic, isolated incidences of RHD had been reported in domesticated rabbits until recently (J. A.V.M,, 2000) . However, RHDV2 infections in wild black-tailed jackrabbit and wild cottontails were confirmed in New Mexico in April 2020 (New Mexico Department of Game and Fish, 2020) and have been spreading to multiple states among domesticated and wild rabbits, significantly diminishing the hope of eradication of RHD in the US. The characteristic clinical signs of RHD caused by RHDV1 and 2 are fulminant viral hepatitis; The affected animals exhibit lethargy, inappetence and fever followed by death or die before showing clinical signs. Although both RHDV types have similar pathogenesis and clinical course, RHDV2 can infect young (< 2-month-old) and adult rabbits and several hare species (Buehler et al., 2020; Dalton et al., 2012; Le Gall-Recule et al., 2017; Velarde et al., 2017) , while RHDV1 infection is limited to adult domestic rabbit populations. RHDV also pose a serious threat to threatened or endangered wild rabbit species, such as Riparian Brush rabbits, Riverine rabbit, Pygmy rabbits or Hispid hare (also called as bristly rabbits) (Villafuerte and Delibes-Mateos) .

European brown hare syndrome virus (EBHSV), another lagovirus (Fig. 1A) , is a highly pathogenic and contagious virus that mainly affects hares, such as European brown hares, mountain hares and Italian hares, although the eastern cottontail was reported to be susceptible to spillover infection of EBHSV (Velarde et al., 2017) . EBSHV was first detected in Sweden in the early 1980s and has since become endemic in Europe (Gavier-Widen and Morner, 1993) . EBSHV causes fatal viral hepatitis with clinical signs similar to those of RHDV, and the mortality rate of EBSH may reach 100% in farmed hares (Abrantes et al., 2012) . Rabbit calicivirus (RCV) and hare calicivirus (HaCV) are non-pathogenic members of the genus Lagovirus (Fig.1A) and have been shown to undergo recombination with RHDV and EBHSV contributing to strain diversity and evolution of viruses (Abrantes et al., 2020; Szillat et al., 2020) .

These caliciviruses are highly contagious, requiring a small number of virus particles for infection, and very stable in the environment. It was reported that RHDV can survive for up to three months in rabbit carcass (Henning et al., 2005) , and bodily fluid, fomites and biting insects are able to spread the virus as mechanical vectors (McColl et al., 2002) . Furthermore, surviving rabbits can shed RDHV for months. Therefore, it is very difficult to control viral transmission once it is spread to wild rabbit populations. Although no vaccine is available for EBSHV, inactivated and myxoma virus-based live vaccines are licensed for RHDV in the EU. In the US, recombinant subunit vaccine for RHDV2 was recently issued emergency use authorization by USDA's Center for Veterinary Biologics in October 2021. However, no specific treatment is available for RHDV and EBSHV, and only strict biosecurity practices and vaccinations are used for prevention and control of the viruses. Considering the detrimental impact of these virus infections on the global rabbit and hare industry and pet rabbits as well as endangered rabbit and hare species, development of effective prophylactic and therapeutic treatment would be a valuable contribution to the limited arsenal of control measures available against these virus diseases.

Caliciviruses such as RHDV and EBSHV have a single-stranded, positive sense RNA genome, which is organized into two major open reading frames (ORFs) (Fig. 1B) .

The ORF1 encodes a polyprotein, which is processed by virus-encoded 3C-like protease (3CLpro) to release mature nonstructural proteins and the major structural protein VP1. This virus polyprotein processing by 3CLpro is an essential step in virus replication and is thus considered a promising target for drug discovery for viruses that encode 3CLpro, such as caliciviruses and coronaviruses. We have previously reported potent 3CLpro inhibitors of caliciviruses including human norovirus Damalanka et al., 2017; Damalanka et al., 2018; Galasiti Kankanamalage et al., 2017a; Galasiti Kankanamalage et al., 2015; Galasiti Kankanamalage et al., 2019; Kim et al., 2012; Mandadapu et al., 2013a; Mandadapu et al., 2013b; Mandadapu et al., 2012; Rathnayake et al., 2020a; Weerawarna et al., 2016) and feline calicivirus and of coronaviruses such as feline infectious peritonitis virus (FIPV) Pedersen et al., 2018) , MERS-CoV (Rathnayake et al., 2020b) , MERS-CoV (Rathnayake et al., 2020b) and SARS-CoV-2 (Dampalla et al., 2021a; Dampalla et al., 2021b) . In this study, we established a fluorescence resonance energy transfer (FRET) assay and a cell-based reporter assay to evaluate 3CLpro inhibitors and identified potent compounds against RHDV1 and 2 and EBSHV. Structure-activity relationship study and 3D homology modelling of 3CLpros of RHDV1 and 2 and EBSHV was also conducted to understand the structural basis for the potency of the compounds, which showed that structural requirements of compounds for the inhibition of 3CLpros are similar among caliciviruses including lagoviruses. Table   1 contains the list of the compounds used in the study.

for FRET assay. The 3CLpro sequences of RHDV1 (FRG strain), RHDV2 (NL2016 strain) and EBHSV (G104 strain) were obtained from GenBank (accession numbers NP_062875.1, QDF46325.1 and QED89978.1, respectively). The codon-optimized, full length 3CLpro coding-sequences with N-terminal 6His tags were synthesized by subtracting the readings of substrate only control from raw fluorescence readings. After confirming the activity of 3CLpros, the inhibitory activity of the compounds was determined against 3CLpros as previously described Perera et al., 2018) . Serial dilutions of each compound (10 mM stock solution in DMSO) were prepared in DMSO or media, and each dilution was added to 25 µl of assay buffer containing the 3CLpro. The concentration of DMSO in each dilution did not exceed 4 % of final concentration. After incubation at RT for 30 min, the mixture was added into 25 µl of assay buffer containing the FRET substrate in a black 96 well microplate, and the plate was incubated at RT for 30 min. The raw fluorescence readings were measured on the fluorescence microplate reader, and the relative fluorescence was calculated by subtracting the values for substrate-only control from the raw values. The 50% inhibitory concentration (IC 50 ) was calculated using the non-linear regression analysis (four parameter variable slope) in GraphPad Prism software version 6.07 (GraphPad Software, La Jolla, CA).

and circular permutated firefly genes. The full-length 3CLpro sequence of RHDV2 was codon-optimized for protein expression in mammalian cells, synthesized by Integrated DNA Technologies (Coralville, IA) and inserted into pcDNA3 H2B-mIFP T2A Mpro (3CLpro) (Addgene, MA) following digesting with BamH1 and ApaI. The resulting plasmid was designated as pcDNA3-RHDV2-3CLpro. A plasmid encoding inactive RHDV2 3CLpro was generated by substituting the nucleophilic Cys with Ala in the active site of 3CLpro in pcDNA3-RHDV2 using site-directed mutagenesis (Agilent's Quik Change mutagenesis kit, Agilent, CA) and designated as pcDNA3-RHDV2-m3CLpro. The pGloSensor TM -30F-DEVDG plasmid (Promega, Madison, WI) contains firefly luciferase gene with a caspase 3/7 cleavage site (DEVDG), which is a circular, permutated form of firefly luciferase (Galban et al., 2013) . To replace the caspase 3/7 cleavage site with a sequence from RHDV NS3/4 cleavage site (VASFEGAN), site-directed mutagenesis was conducted using primers containing the cleavage sequence. The primer sequences are Forward: 5'-GATCCGTGGCCTCATTCGAGGGTGCA-3' and Reverse: 5'-AGCTTGCACCCTCGAATGAGGCCACG-3'. The resulting plasmid was designated as pGlo-RHDV. The plasmid also contains Renilla luciferase as an expression control.

Assay. One-day old 293T cells in a 48-well plate were co-transfected with pGlo-RHDV and pcDNA3-RHDV2-3CLpro or pcDNA3-RHDV2-m3CLpro. About 16 hr later, medium was replaced with new medium containing serial dilutions of each compound or mock (medium), and the cells were incubated for 37°C for 5 hours. Then, the cells were lysed and firefly and Renilla luminescence were measured following the manufacturer's directions (Dual luciferase kit, Promega, Madison, WI) on a luminometer (GloMax® 20/20

Luminometer, Promega, Madison, WI). Firefly luciferase was normalized against Renilla luciferase, and the 50% effective concentration (EC 50 ) of each compound was calculated by GraphPad Prism software using a variable slope (GraphPad, La Jolla, CA). Figure 2 illustrates the cell-based reporter assay.

To determine the cytotoxicity of the compounds, semi-confluent HaCV (E15-431 strain) were obtained from Genbank and aligned using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) (Madeira et al., 2019) . To generate a phylogenetic tree, the 3CLpro amino acid sequences of RHDV1 (46 sequences), RHDV2

(39 sequences), EBHSV (6 sequences), RCV (39 sequences) and HaCV (5 sequences) were obtained from Genbank and aligned using Clustal Omega and a phylogenetic tree was generated using the maximum Likelihood method and Whelan and Goldman model (Whelan and Goldman, 2001) in MEGA X (Kumar et al., 2018) and annotated using iTOL v6.4 (Letunic and Bork, 2021 

the FRET assay. Activities of the recombinant RHDV1 and 2 and EBHSV 3CLpro were confirmed prior to inhibition assay. Each 3CLpro showed gradual increase in activity over time in a similar trend (Fig. 3A) . Next, we evaluated the compounds against each 3CLpro

in the assay to determine the IC 50 values against each 3CLpro (Fig. 3B) reported to be about 0.5 µM in the FRET assay by us (Perera et al., 2018) . GC376 is a dipeptidyl compound that potently inhibits various coronaviruses Perera et al., 2018) and contains Leu and benzyl ring at the R 3 and R 1 positions, respectively, and a bisulfite adduct warhead (R 4 ) that converts to an aldehyde form (Table 1 ) . Substitution of the bisulfite adduct warhead and Leu at the R 3 (GC376) with an aldehyde warhead and Cha (GC543) led to greatly increased inhibitory activity against all 3CLpros. We have previously showed that compounds with bisulfite adduct vs aldehyde warheads exhibit similar activity in the FRET and cell-based assays (Galasiti Kankanamalage et al., 2017b) . Therefore, substitution of Leu with Cha at the R 3 would be responsible for the observed increase in potency. Replacing benzyl ring (GC543) with mbenzyl ring (GC583) at R 1 slightly further increased potency against all tested 3CLpros.

However, replacing the aldehyde warhead (GC583) with (C=O)CONH cyclopropyl (GC591) markedly decreased the inhibitory activities against all 3CLpros, but this reduction in activity was not as profound as having Leu at R 3 (GC376). In GC772, the carbamate moiety of GC583 was replaced with a sulfonamide linkage, which decreased potency against all tested 3CLpros. NPI52, a tripeptidyl compound, has homologous structural elements with GC376 except that NPI52 has an aldehyde warhead and an additional residue of 1-naththylalanine that corresponds to the P3 position. The inhibitory activity of NPI52 was more potent than GC376 but less than GC543 and GC583 against the tested 3CLpros. Dose-response curves of GC589 against RHDV1 and 2 and EBHSV 3CLpros are shown in Fig. 3C .

Since lagoviruses do not grow in cell culture, we examined the potency of the compounds against RHDV2 in a cell-based reporter assay ( Fig. 2A and B) . The inactive RHDV 3CLpro was also included as a control and had minimal luminescence in the assay (<1% of luminescence of active 3CLpro). All the compounds that were included in the study showed minimal cytotoxicity at 100 µM in 293T cells (Fig. 4A) . The EC 50 values of these compounds against RHDV2 3CLpro ranged from 0.46 ~ 9.80 µM in 293T cells (Fig. 4A ).

In this assay system, GC543 and GC583 exhibited most potent activity, which is consistent with the results from the FRET assays (Fig. 3B ). GC376 and GC772 showed substantially reduced activity compared to GC543 or GC583 by 9.7~11.6-fold, which is comparable to the fold reductions in potency observed in the FRET assay (13.4~15.1fold). In general, GC591, GC772 and NPI52 showed similar trend of activity compared to GC376 in the cell based and FRET assays except for GC591, which had somewhat decreased activity in the cell-based assay. The dose-dependent curves of GC543 and GC583 against RHDV2 in the cell-based assay are shown in Fig. 4B . showed that the catalytic residues H27, D44 and C104 (Oka et al., 2011) are conserved in RHDV, EBHSV, RCV and HaCV 3CLpros (Fig. 5A) . Phylogenetic analysis showed the 3CLpros of GII lagoviruses, EBHSV and HaCV, can be clustered into the same main branch, while the 3CLpros of GI lagoviruses, RHDV1 and 2 and RCV, belonged to other branches (Fig. 5B) . Interestingly, the clades of 3CLpros of GI lagoviruses, RHDV1 and 2 and RCV, are interspersed phylogenetically, which may reflect recombination events that have occurred among these pathogenic and non-pathogenic lagoviruses. It has been reported that lagoviruses have high capacity of recombination within lagoviruses with hotpots between the structural and nonstructural genes (Abrantes et al., 2020; Mahar et al., 2021; Szillat et al., 2020) , which is frequently observed for other caliciviruses (Bull et al., 2005; Ludwig-Begall et al., 2018) 3.4. Three-dimensional homology structural models for 3CLpro of RHDV and EBHSV 3CLpro. The homology-based 3CLpro structural models of RHDV1, RHDV2, and EBHSV are shown in figure 6A and B with the catalytic residues indicated in red. RHDV1

and RHDV2 3CLpro models are very closely homologous (Fig. 6A ) with a root-meansquare deviation (RMSD) of 0.24 Å between the Cα atoms of residues 27-104 containing the catalytic residues. However, the 3D model of EBSHV 3CLpro showed a lower structural homology with RHDV1 and RHDV2 3CLpro (Fig. 6B ) with a RMSD of 9.9 Å between the Cα atoms from residues 27-104. A crystal structure of human norovirus 3CLpro-GC376 complex was included as its overall structural folds resembles those of lagoviruses (Fig. 6C) . The nucleophile residue (C139) of human norovirus forms a covalent bond with GC376 superimposes with the catalytic residues of lagoviruses (Fig.  6D ). Despite some differences in the overall structures in these models, the catalytic residues in the catalytic site of all three models align very closely (Fig. 6D ). Highconfidence models of the 3CLpro of RHDV2, which adopts a similar fold to other structures such as human norovirus 3CLpro ( Fig. 6A and C) were docked with GC376 and GC583 to compare the binding modes. The GC376 inhibitor forms hydrogen bond interactions with H27, T99, H101, H119, T120 and K122 (Fig. 7A) . Similarly, GC583 forms interactions with H27, T99, H101, H119, and K122 ( Fig. 7B ) but does not interact with T120. The main difference is observed in the P2 position of the inhibitors where the cyclohexyl group of GC583 occupies the S2 subsite that is formed by H27, D44 and L82.

The benzyl and m-chlorobenzyl rings of GC376 and GC583 respectively are positioned in a hydrophobic cleft in the S4 subsite formed by T81, A92 and L124 ( Fig. 7C and D) .

Following the unexpected report of RHDV2 infection in native North American jackrabbits and cottontails in New Mexico in 2020 April, this highly pathogenic calicivirus has been confirmed in wild rabbits and hares in the southwest states in the US (U.S. Food and Drug Administration, Nov 19, 2020) and is now considered endemic or near endemic in these regions. Before this recent spread of RHDV2 in wild rabbits and hares, detection of RHDV2 infection had been limited to isolated cases of domestic and feral rabbits in the US. Outside the US, RHDV1 and subsequently RHDV2 have become endemic in many parts of the world with a substantial economic and ecological impact on the rabbit industry and wild rabbit populations worldwide. However, efforts to investigate potential antiviral treatments have been generally lacking, and specific treatment options are not available for RHD as well as EBHS, which is also endemic in most parts of the world (Du et al., 2019; Urakova et al., 2016) . Caliciviruses, coronaviruses and picornaviruses encode viral proteases 3CLpro or 3Cpro, which are responsible for virus polyprotein cleavage and an essential component of virus replication. These viral proteases adopt chymotrypsin-like protease folds and are functionally and structurally conserved among calicivirus, coronavirus and picornaviruses although protein sequence homology may vary substantially among them. We have previously generated focused libraries of 3CLpro/3Cpro inhibitors and reported the in vitro and/or in vivo potency of some protease inhibitors against caliciviruses, coronaviruses and picornaviruses (Dampalla et al., 2021a; Kim et al., 2016; Kim et al., 2012; Kim et al., 2015; Rathnayake et al., 2020a; Rathnayake et al., 2020b) . In this study, we evaluated the activity of select protease inhibitors including GC376 and its derivatives against RHDV1 and 2 and EBHSV 3CLpros and conducted structure-activity relationship studies using the FRET and cell-based reporter assays.

All the compounds we tested showed potent activity against RHDV1 and 2 and EBHSV 3CLpros in the FRET and the cell-based reporter assays, and the activity of each compound was comparable among RHDV1, RHDV2 and EBHSV 3CLpro. GC376 is a dipeptidyl compound that was shown to be broadly effective against various coronaviruses, including FIPV, a highly virulent feline coronavirus, MERS-CoV, SARS-CoV-2, as well as some caliciviruses and picornaviruses Kim et al., 2012; Kim et al., 2015; Pedersen et al., 2018; Perera et al., 2018; Vuong et al., 2020) and

is currently under commercial development as an antiviral drug for FIP. GC376 is a bisulfite adduct prodrug of the corresponding parent aldehyde GC373 and has glutamine surrogate, Leu and benzyl group in the P1, P2 (R 3 group) and P3 (R 1 group) position, respectively (Table 1) . Bisulfite adduct compounds convert to their aldehyde counterparts, and they exhibit similar potency in in vitro assays Mandadapu et al., 2013b; Perera et al., 2018) . We have previously reported that the antiviral activity of GC376 is slightly more potent against FIPV compared to aldehyde compounds GC543 and GC583, which have Cha (cyclohexylalanine) moiety at R 4 and a benzyl group or m-chlorobenzyl group at R 1 , respectively (Perera et al., 2018) . In contrast, GC543 and GC583 have significantly improved activity against RHDV1 and 2 and EBHSV 3CLpros over GC376, which indicates that the Cha moiety at R 3 is more suitable for these 3CLpros. The preference of Cha moiety over Leu at R 3 was also observed for 3CLpro of human norovirus, a calicivirus in the Norovirus genus (Galasiti Kankanamalage et al., 2015) and feline calicivirus that belongs to the Vesivirus genus .

However, substitution of the benzyl group (GC543) with m-chlorobenzyl (GC583) did not markedly increase the activity of a compound against RHDV1 and 2 and EBHSV 3CLpros, unlike human norovirus 3CLpro. The results from the cell-based reporter assays we have established for RHDV and EBHSV correlated well with those determined in the FRET assay. The EC 50 values from the reporter assay were generally higher than the IC 50 values from the FRET assay, which is likely due to transient expression of high levels of 3CLpro in cells. One of the protease inhibitors tested, GC376, has an IC 50 value of 0.5 µM against FIPV 3CLpro in the FRET assay (Perera et al., 2018) and an EC 50 value of 0.02~0.04 µM against the replication of FIPV in cell culture Kim et al., 2015) . Considering the in vivo efficacy of GC376 in cats with FIP Pedersen et al., 2018) , all tested compounds, especially GC543 and GC583, seem to have a good potential for further development as a drug for these viral infections. GC583

has been previously shown to have in vivo efficacy by significantly decreasing murine norovirus replication in the intestinal tract in mice [compound 16 in (Galasiti Kankanamalage et al., 2015) ].

Notably, despite the sequence homology differences in the 3CLpros of RHDV and EBHSV, the 3D homology modelling showed that the catalytic site topology of these lagovirus 3CLpros appears to be highly conserved, which may explain the comparable potency of compounds against RHDV1 and 2 and EBHSV 3CLpros. The preference of Cha over Leu at the P2 position is also shared among many caliciviruses, including lagoviruses, human norovirus and feline calicivirus. The crystal structures of human norovirus 3CLpro bound to GC376 or GC583 have previously revealed that Cha at the P2 position is filling the hydrophobic S2 subsite of 3CLpro more tightly than Leu , which is also predicted in the homology model of 3CLpro of RHDV2, highlighting the similar structural requirements for 3CLpro inhibition of caliciviruses.

In summary, we assessed the potency of select protease inhibitors against RHDV1 and 2 and EBHSV using the in vitro assays and conducted structure-activity relationship and 3D homology modelling studies. Using the FRET and the cell-based reporter assays, we identified compounds that display potent inhibitory activities against all three lagovirus 3CLpros. To our knowledge, this is the first report on antiviral compounds that target 3CLpro for development of effective inhibitors broadly acting against pathogenic lagovirus. representations in panels C and D. The S1, S2 and S4 subsites are indicated in parenthesis.

Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review

Changes to taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on

Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19

Rabbit calicivirus infection confirmed in Iowa rabbitry

Lagovirus europeus GI.2 (rabbit hemorrhagic disease virus 2) infection in captive mountain hares (Lepus timidus) in Germany

Norovirus recombination in ORF1/ORF2 overlap

Epidemiology and current situation of viral haemorrhagic disease of rabbits and the European brown hare syndrome in Italy

Antiviral Drug Discovery: Norovirus Proteases and Development of Inhibitors

Variant rabbit hemorrhagic disease virus in young rabbits

Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease

Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease

Structure-guided design, synthesis and evaluation of oxazolidinone-based inhibitors of norovirus 3CL protease

Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease

Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection

The PyMOL Molecular Graphics System

Evaluation of the Therapeutic Effect of a Flavonoid Prescription against Rabbit Hemorrhagic Disease In Vivo

Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease

Structure-based exploration and exploitation of the S4 subsite of norovirus 3CL protease in the design of potent and permeable inhibitors

Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies

Putative structural rearrangements associated with the interaction of macrocyclic inhibitors with norovirus 3CL protease

Imaging proteolytic activity in live cells and animal models

Descriptive epizootiological study of European brown hare syndrome in Sweden

Emerging Infectious Diseases of Rabbits

Survival of rabbit haemorrhagic disease virus (RHDV) in the environment

The Phyre2 web portal for protein modeling, prediction and analysis

Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor

Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses

Potent inhibition of feline coronaviruses with peptidyl compounds targeting coronavirus 3C-like protease

Broad-spectrum inhibitors against 3C-Like proteases of feline coronaviruses and feline caliciviruses

MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms

Large-scale lagovirus disease outbreaks in European brown hares (Lepus europaeus) in France caused by RHDV2 strains spatially shared with rabbits (Oryctolagus cuniculus)

Detection of a new variant of rabbit haemorrhagic disease virus in France

Interactive Tree Of Life (iTOL) v5: an online tool for phylogenetic tree display and annotation

Norovirus recombinants: recurrent in the field, recalcitrant in the lab -a scoping review of recombination and recombinant types of noroviruses

The EMBL-EBI search and sequence analysis tools APIs in 2019

Frequent intergenotypic recombination between the non-structural and structural genes is a major driver of epidemiological fitness in caliciviruses

Potent inhibition of norovirus by dipeptidyl alpha-hydroxyphosphonate transition state mimics

Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors

Potent inhibition of norovirus 3CL protease by peptidyl alpha-ketoamides and alpha-ketoheterocycles

Evidence for insect transmission of rabbit haemorrhagic disease virus

Rabbit Hemorrhagic Disease Cause for Rabbit Mortality

Comparative site-directed mutagenesis in the catalytic amino acid triad in calicivirus proteases

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Protease inhibitors broadly effective against feline, ferret and mink coronaviruses

Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors

Structure-Guided Optimization of Dipeptidyl Inhibitors of Norovirus 3CL Protease

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoVinfected mice

Schrödinger Release 2019-4: Protein Preparation Wizard; Epik

Impact; Prime; Glide; LigPrep; Induced Fit Docking protocol

Full-genome sequencing of German rabbit haemorrhagic disease virus uncovers recombination between RHDV (GI.2) and EBHSV (GII.1)

Purification and Biochemical Characterisation of Rabbit Calicivirus RNA-Dependent RNA Polymerases and Identification of Non-Nucleoside Inhibitors

Spillover Events of Infection of Brown Hares (Lepus europaeus) with Rabbit Haemorrhagic Disease Type 2 Virus (RHDV2) Caused Sporadic Cases of an European Brown Hare Syndrome-Like Disease in Italy and Spain

Oryctolagus cuniculus. The IUCN Red List of Threatened Species 2019. The IUCN Red List of Threatened Species

Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication

Structure-based design and synthesis of triazole-based macrocyclic inhibitors of norovirus protease: Structural, biochemical, spectroscopic, and antiviral studies

A general empirical model of protein evolution derived from multiple protein families using a maximum-likelihood approach

TM-align: a protein structure alignment algorithm based on the TM-score

The authors would like to thank David George for technical assistance.